Search PubMed⌕ Search

Biomedical subjects

C W Israel

Publications and source records attributed to C W Israel.

At least 19 recordsLinked to original sources
PubMed2006

[Cardiac resynchronization therapy in patients with permanent atrial fibrillation--with or without atrial lead?].

A 59-year-old patient received a biventricular defibrillator for cardiac resynchronization therapy (CRT) due to severe heart failure and a left bundle branch block. He had suffered from mitral stenosis and had received valve replacement 16 years earlier. Because he had permanent atrial fibrillation since that time, no atrial lead was implanted. His symptoms improved with CRT until he received adequate shock therapy for a rapid ventricular tachyarrhythmia. After that his symptoms deteriorated again severely. The ECG recorded during an unscheduled follow-up visit 1 week after the shock explains the reason.

Atrial Fibrillation↗
PubMed2006

Use of telemedicine in the diagnosis of paroxysmal atrial fibrillation and to monitor the effect of antiarrhythmic drug therapy.

We present the case of a patient with highly symptomatic tachyarrhythmias for 2 years without any arrhythmia documentation despite numerous ECG and Holter registrations. By means of telemedicine, it was possible to document the arrhythmia--in this case atrial fibrillation--within 10 days and to start antiarrhythmic drug treatment with flecainide and metoprolol. This case demonstrates the diagnostic potential of telemedicine in patients with recurrent episodes of tachyarrhythmias in whom episodes are not sufficiently frequent to allow diagnosis by Holter monitoring. Telemedicine may also be advantageous for ECG monitoring during the early phase after cardioversion or initiation of specific antiarrhythmic pharmacotherapy in order to detect potential drug-induced proarrhythmic changes.

Anti-Arrhythmia Agents↗
PubMed2006

[Indication for cardiac resynchronization therapy: Consensus 2005].

The indication for cardiac resynchronization therapy (CRT) using biventricular pacing or ICD systems has to be highly differentiated to optimize the proportion of patients who derive significant symptomatic benefit from this therapy, on the one hand, and to avoid this invasive treatment in patients with a low probability of clinical success of CRT, on the other hand. As a consensus in 2005, it can be put forward that there is sufficient evidence for an indication for CRT from clinical studies for the following characteristics: 1) Heart failure in NYHA functional class III or IV (if cardiac recompensation to class III is at least temporarily successful), 2) left ventricular ejection fraction < or =35%, 3) QRS duration >130 ms, particularly if left bundle branch block is present, 4) sinus rhythm. In addition, available data also suggest an indication for CRT in patients with atrial fibrillation if the other criteria listed above are met. The indication for CRT is unclear in patients with other intraventricular conduction delay (particularly right bundle branch block) while patients with left bundle branch block and a QRS duration of 120-130 ms seem to benefit if echocardiographic criteria demonstrate ventricular dyssynchrony. Since a multiplicity of echocardiographic criteria of ventricular dyssynchrony exists which is neither standardized nor evaluated in large-scale randomized trials, ventricular dyssynchrony on echocardiography alone cannot be regarded as an established indication for CRT without a QRS complex > or =120 ms. Similarly, whether heart failure in functional state NYHA II should be regarded as a CRT indication is currently being investigated in the randomized RAFT and MADIT-CRT trials.

Arrhythmias, Cardiac↗
PubMed2005

[Technical requirements for early defibrillation: what are the capabilities of automated external defibrillators].

Modern automated external defibrillators (AEDs) offer a variety of technical improvements which increase the efficacy of early defibrillation, facilitate the application by not or minimally trained persons and improve safety. The development of biphasic shocks allows better myocardial protection, the use of lithium batteries, and a marked decrease of AEDs, in size. Microprocessors realize complex acoustic and visual prompts which lead the user through all steps of cardiopulmonary resuscitation (CPR) according to current guidelines. The design of AEDs has been simplified; many devices provide only a single button which can be used for all active processes. Memory functions record the whole CPR with all details which can be transferred to other computers and analyzed off-line. The introduction of AEDs has reduced the delay between collapse and defibrillation to less than 4 min in several studies thus increasing the success of CPR and the proportion of patients dismissed from hospital alive and without neurological deficit. Up to 93% of untrained volunteers were able to successfully complete defibrillation with the use of an AED, sixth-form pupils without experience in CPR were only few sec slower with an AED than staff of emergency medical services. The ability to perform CPR after defibrillation guided by the AED depends primarily on the clarity of acoustic prompts which have to consider the terms and abbreviations of the respective language. Currently available AEDs surpass performance goals of the AHA. However, all devices exhibit advantages and disadvantages which will be discussed in this review.

Cardiopulmonary Resuscitation↗
PubMed2003

Prediction of early recurrence of atrial fibrillation after external cardioversion by means of P wave signal-averaged electrocardiogram.

BACKGROUND: Therapy of atrial fibrillation by electrical cardioversion (CV) is limited by the high rate of recurrences. Early recurrence of atrial fibrillation (ERAF) occurs in a subgroup of patients whose characteristics are poorly defined. This prospective study was performed to evaluate if the P wave signal-averaged ECG (PSAECG) is able to identify patients with an increased risk of ERAF after CV. METHODS: Patients with an indication for elective external CV were enrolled. After successful CV, PSAECGs were recorded at 0.5, 1, 24 h and 1 week. The ability of PSAECG parameters (signal-averaged P wave duration, PWD; root-mean-square of the voltage of the terminal 20, 30, and 40 ms of the signal-averaged P wave; RMS20, RMS30, RMS40) to predict ERAF (prospectively defined as AF recurrence within 4 h after CV) was assessed. RESULTS: Of 111 consecutive patients, 7 experienced ERAF, 30 patients had AF recurrence later during the 1-week follow-up. Patients with ERAF had a significantly prolonged signal-averaged PWD compared to patients who remained in SR (194+/-16 ms vs 139+/-3 ms at 0.5 h, p<0.001). As ROC analysis revealed, a PWD >/=154 ms at 30 min after CV had the highest predictive accuracy for ERAF (sensitivity 100%, specificity 82%, positive predictive value 33%, negative predictive value 100%). Other parameters of the PSAECG did not reveal significant differences between patients with and without ERAF. CONCLUSIONS: The PSAECG provides a sensitive noninvasive tool for detection of patients at risk of ERAF. Thus identified, tailored pharmacological therapy is conceivable to prevent ERAF.

Aged↗
PubMed2003

Incremental programming of atrial anti-tachycardia pacing therapies in bradycardia-indicated patients: effects on therapy efficacy and atrial tachyarrhythmia burden.

AIMS: Efficacy of pace-termination of atrial arrhythmias (ATP) may depend on atrial cycle length and regularity. Whether device programming of ATP therapies can improve ATP efficacy and alter atrial tachyarrhythmia burden is unknown. METHODS AND RESULTS: ATP efficacy was evaluated in 61 patients (39 males; 66 +/- 10 years) with a standard indication for pacing, 95% with a history of AT/AF. Each patient was implanted with a novel DDDRP pacemaker capable of delivering ATP therapy. ATP efficacy and AT/AF frequency and burden were compared within each patient during a period of nominal ATP programming (NP) followed by a period of aggressive incremental programming (IP). Adjusted ATP-termination efficacy was higher during IP than during NP (54.8% vs 37.9%, P < 0.05). No differences in AT/AF frequency (3.3 +/- 5.9 vs 3.2 +/- 6.9 day(-1)) or burden (18 +/- 28% vs 18 +/- 29%) were observed comparing NP with IP. The majority of episodes during both the NP (81%) and IP (77%) periods terminated within 10 min. Episodes lasting 24 h or more accounted for only 0.4% of the episodes in both groups. but accounted for 38% of the average burden during NP and 51% during IP. CONCLUSIONS: Device programming of ATP therapies can influence the number of treated episodes and the efficacy of ATP therapies although arrhythmic frequency and burden may not change. Total atrial arrhythmia burden is disproportionately influenced by long (>24 h) episodes.

Aged↗
PubMed2002

Single-lead VDD-pacing system incorporating high impedance stimulation: a multicentre study.

AIM: The purpose of this study was to evaluate the performance of a new VDD pacing system incorporating a high impedance, single-pass VDD lead. The new lead is a bipolar, steroid-eluting, high impedance lead with a full-ring atrial dipole. METHODS AND RESULTS: The system was implanted in 46 patients with high degree atrioventricular (AV) block. Patients were followed at pre-discharge, 6 weeks, and 3 months. The mean measured P-wave amplitude was stable, with values between 1.18 and 1.43 mV. Atrial sensing was reliable during short-term evaluation at rest and in the sitting position, with AV-synchronous stimulation between 98.79 +/- 6.90% and 99.73 +/- 1.47%. Holter recordings after 6 weeks demonstrated AV-synchronous stimulation in 99.57 1.03% of all P-waves. Lead impedance was stable during follow-up, with mean values between 1000 and 1167 Q. Mean ventricular pacing thresholds (at 0.5 ms) were 0.47 V at implant, 0.49 V at pre-discharge, 0.74 V at 6 weeks, and 0.72 V at 3 months. R-wave amplitude remained stable between 14.9 and 16.7 mV during follow-up. CONCLUSION: This new single-pass VDD lead system provided reliable atrial sensing and stable high impedance stimulation during a 3-month follow-up period.

Aged↗
PubMed2001

[Mode-switching algorithms: programming and usefulness].

BACKGROUND: Automatic mode switching is defined as the ability of a pacemaker to reprogram itself from tracking to non-tracking mode in response to atrial tachyarrhythmias, and to regain tracking mode as soon as the tachyarrhythmia terminates. In contrast to upper rate behavior, mode switching does not only limit atrial tracking at a certain rate but actively drives the ventricular pacing rate back to lower rate or sensor rate as long as the atrial tachyarrhythmia persists. In contrast to DDD with mode switch, AV synchrony may be lost in DDIR mode if the sinus rate exceeds the sensor rate. DDD pacing with mode switching represents a valuable option in patients with AV block and paroxysmal atrial tachyarrhythmias. It may prevent the transition from paroxysmal to permanent atrial fibrillation after AV node ablation to a higher extent than VVI(R) pacing. On the other hand, patients with sinus node disease and normal AV conduction may benefit from DDIR mode with long AV interval. Mode switching should provide a rapid, sensitive and specific detection of atrial tachyarrhythmias, fast switch to non-tracking mode without ventricular pacing at the upper rate limit, adequate ventricular rate during the atrial tachyarrhythmia, rapid, sensitive and specific detection of conversion to sinus rhythm and fast switch back to tracking mode. In addition, oscillations between DDD and DDI mode with sudden ventricular rate changes should be avoided. MODE-SWITCHING ALGORITHMS: To achieve these aims, different mode-switching algorithms have been developed which all show specific disadvantages: reliable but slow response to atrial tachyarrhythmias, fast but unspecific switch to non-tracking mode, mode oscillations, inclination to inadequate mode-switching due to ventricular far-field sensing, failure to perform modeswitching during atrial flutter or intermittent atrial undersensing. Some of these problems can be avoided by careful atrial lead implantation providing atrial signals above 2 mV and avoiding ventricular far-field signals. Programming of mode-switching related parameters (e.g. atrial rate and number of fast beats required for mode switch), atrial blanking times, and atrial sensitivity can solve some of the problems with mode switching. Clinical results show a strong influence of device programming and atrial undersensing on mode-switching performance. Some data suggest a superiority of fast mode-switching algorithms with regard to clinical symptoms. However, loss of AV synchrony during sinus rhythm due to premature or inadequate mode switching may limit the benefit of fast mode switching. FURTHER DEVELOPMENTS: Improved performance may be achieved by a combination of different mode-switching algorithms (e.g. one algorithm for detection of atrial fibrillation, another one for detection of atrial flutter). In addition, programmability of several algorithms (e.g. mean atrial rate, beat-to-beat, x out of y) within the same device and atrial cycle-dependent sensitivity adjustment similar to automatic gain control in implantable defibrillators may further increase the clinical use of automatic mode switching.

Algorithms↗
PubMed2001

[P-wave signal averaging-ECG: normal values and reproducibility].

Signal averaging techniques are used for detection of low amplitude, high frequency signals in the surface ECG. P-wave signal-averaging has been used to predict the risk for development of atrial tachyarrhythmias in patients with structural heart disease. There is, however, a lack of prospective studies evaluating normal values of the P-wave signal-averaged ECG in healthy individuals. Moreover, day-to-day reproducibility of results of P-wave signal-averaging is not precisely known. Thus, the aim of this study was to determine normal values and reproducibility of time-domain P-wave signal-averaging in a large cohort of healthy volunteers. A commercially available device (MAC 5000, Marquette Hellige) was used for signal-averaging. A vector magnitude was calculated from Frank's orthogonal leads after P-waves were sampled and filtered with a spectral filter using fast fourier transform. We examined 123 volunteers without cardiovascular disease at two occasions. Mean P-wave duration was 114 +/- 13 ms for the overall study population. There was a slight but statistically significant increase in filtered P-wave duration with age (r = 0.32, p < 0.001). All values were reliably reproducible upon the second examination (r = 0.624 to 0.706, p < 0.0001). These results may serve as a future reference to other studies examining patients with structural heart disease.

Adult↗
PubMed2001

Prevalence, characteristics and clinical implications of regular atrial tachyarrhythmias in patients with atrial fibrillation: insights from a study using a new implantable device.

OBJECTIVES: This study prospectively analyzed atrial tachyarrhythmia (AT) organization and antitachycardia pacing (ATP) success in patients with an implanted device for AT therapy. BACKGROUND: In patients with atrial fibrillation (AF), the incidence of regular, slow ATs amendable by ATP is unknown. METHODS: Forty patients with previously documented AT (70% with AF) received a new pacemaker with atrial electrogram (AEG) storage and atrial ATP capabilities for standard pacing indications. The AEGs acquired during the first month (study phase 1) were classified into high (type I), intermediate (type II) and low (type III) degrees of organization. Atrial ATP was then activated, and treated AT episodes were retrieved three and six months after implantation (study phase 2). RESULTS: Of 824 AEGs retrieved before ATP activation (study phase 1), 351 (43%) were classified as type 1, 47% as type II and 10% as type III. Episodes of AT starting as type I (35%) and type II or III (65%) maintained their type over 1 min in 73%. All patients with an exclusive history of AF also showed type I AEGs. In 361 subsequently treated AT episodes (study phase 2), ATP was successful in 62% of type I and 34% of type II episodes, but not in type III (p < 0.0001). CONCLUSIONS: The majority of patients with a history of AF show not only disorganized but also highly organized AT episodes, which can be successfully terminated by ATP.

Aged↗
PubMed2001

Discrimination between ventricular and supraventricular tachycardia by dual chamber cardioverter defibrillators: importance of the atrial sensing function.

Although the addition of atrial sensing in dual chamber ICDs may improve the ability of the device to discriminate between supraventricular (SVT) and ventricular tachycardia (VT), atrial sensing errors may also negatively affect tachycardia classification. This prospective study evaluated the incidence of atrial sensing errors in a dual chamber ICD and their impact on VT/SVT discrimination. In 145 patients, a dual chamber ICD (Defender) was implanted. Analysis of 1,241 tachycardia episodes stored during a mean follow-up of 14+/-8 months revealed atrial sensing errors in 817 (66%) episodes. Upon expert review, device-based classification was confirmed in 509 (98%) of 522 SVT episodes. No false device-based SVT classification was related to atrial sensing errors. Of 719 episodes classified as VT by the device, 645 (90%) were confirmed. There were 74 episodes of false-positive VT detection. Of these, 63 were related to atrial sensing errors: atrial undersensing in 58 (92%) and atrial oversensing in 5 (8%) episodes. Atrial sensing errors led to incorrect VT/SVT discrimination in 51 (4%) of 1,241 episodes. Only the occurrence of paroxysmal atrial fibrillation and abdominal site of device implantation showed a significant influence on false VT/SVT discrimination. Atrial sensing errors are frequently encountered in dual chamber ICDs. Due to the VT/SVT discrimination algorithm, atrial sensing errors only led to misclassification in 4 % of all episodes, mainly due to atrial undersensing. No VT underdetection due to atrial oversensing occurred.

Algorithms↗
PubMed2001

Pace-termination and pacing for prevention of atrial tachyarrhythmias: results from a multicenter study with an implantable device for atrial therapy.

INTRODUCTION: Patients with bradycardia requiring permanent pacing frequently suffer from additional atrial tachyarrhythmias (ATs). This study evaluated the safety and efficacy of atrial antitachycardia pacing (ATP) and the performance of pacing for AT prevention implemented into a new pacemaker. METHODS AND RESULTS: In patients with conventional indications for permanent pacing, an investigational DDDRP pacemaker (Medtronic AT500, model 7253) was implanted. The primary study objectives were to determine the safety of overall device functioning and its efficacy in terminating spontaneous AT. A secondary endpoint was to determine the reliability of AT detection. Pacemaker memory functions were used to analyze the impact of dedicated pacing algorithms on AT prevention. In 33 European and Canadian centers, 325 patients were enrolled (mean follow-up 2.3+/-1.3 months). Complication-free survival at 3 months was 88%. In 2,145 episodes stored with atrial electrograms, AT detection was confirmed in 97%. The algorithm for continuous overdrive pacing increased the percentage of atrial pacing to 97%. After ATP activation, 16,683 of 52,468 AT episodes were treated (120 patients). Of these, 8,903 episodes (53%) were terminated successfully by ATP. No proarrhythmic effect of preventive pacing or atrial ATP was observed. Preventive pacing algorithms increased the median percentage of atrial pacing from 62% to 97%. However, the number of AT/AF (atrial fibrillation) episodes (4.1 vs 4.1 per patient per day) and the time in AT/AF (13.7% vs 12.8%) was not significantly different before and after activation of preventive pacing. CONCLUSION: DDDRP pacing with a new system for AT therapy was safe and associated with successful pace-termination of AT in 53% of episodes. Preventive pacing and atrial ATP algorithms represent two new functions that can be implemented safely into pacemaker systems for nonpharmacologic treatment of ATs in patients requiring pacemaker therapy.

Adolescent↗
PubMed2000

Current status of dual-sensor pacemaker systems for correction of chronotropic incompetence.

Rate-adaptive pacing has been shown to improve exercise capacity in patients with chronotropic incompetence. However, all sensors used to adapt the pacing rate to meet metabolic demands show typical limitations. To overcome these, concepts using 2 sensors for rate adaptation have been developed, combining an unspecific but fast-reacting sensor with a specific but slower-reacting one. Clinical performance of these dual-sensor pacemaker systems is related to 3 factors: (1) choice of sensors, (2) mode of sensor integration, and (3) algorithms for automatic optimization of the integrated sensor response. Clinical studies using dual-sensor rate-adaptive pacing systems have demonstrated their ability to mimic normal sinus rate during different forms of exercise, avoiding inadequate or delayed rate response. However, to avoid combining the disadvantages of both single sensors, dual-sensor rate-adaptive systems need effective automatic algorithms. Sensor cross-check should be quick and combine fast reactivity and high specificity, particularly so as to prevent overpacing. Programmable rate response-related parameters should continuously be optimized. The pacemaker should provide diagnostic facilities during exercise to simulate short-term sensor performance at different settings and memory functions to evaluate long-term sensor performance. Assessment and eventually deactivation of all automatic functions should be possible. Finally, even with automatic algorithms for sensor optimization, maximal benefit from a dual-sensor system can only be achieved if the physician is able to identify and correct pitfalls of each system.

Algorithms↗